BI
CBIO

BVF Inc’s Crescent Biopharma CBIO Stock Holding History

BVF Inc’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.5M Hold
2,748,763
– – 1.27% 20
2026
Q1 		$50.5M Hold
2,748,763
– – 1.61% 21
2025
Q4 		$32.6M Buy
2,748,763
+1,360,900
+98% +$17.3M 1.1% 27
2025
Q3 		$16.5M Hold
1,387,863
– – 0.67% 32
2025
Q2 		$22.4M Buy
1,387,863
+1,292,420
+1,354% +$27.3M 0.8% 23
2025
Q1 		$2M Hold
95,443
– – 0.08% 46
2024
Q4 		$2.38M Hold
95,443
– – 0.08% 48
2024
Q3 		$1.61M Hold
95,443
– – 0.05% 49
2024
Q2 		$2.69M Hold
95,443
– – 0.08% 50
2024
Q1 		$28.6M Hold
95,443
– – 0.79% 31
2023
Q4 		$22.5M Hold
95,443
– – 0.56% 36
2023
Q3 		$14.3M Hold
95,443
– – 0.39% 38
2023
Q2 		$16.6M Hold
95,443
– – 0.46% 38
2023
Q1 		$12M Hold
95,443
– – 0.44% 46
2022
Q4 		$28.9M Hold
95,443
– – 1.22% 29
2022
Q3 		$5.27M Hold
95,443
– – 0.22% 60
2022
Q2 		$5.71M Hold
95,443
– – 0.28% 56
2022
Q1 		$10.9M Hold
95,443
– – 0.44% 55
2021
Q4 		$13.7M Hold
95,443
– – 0.5% 48
2021
Q3 		$20.9M Hold
95,443
– – 0.82% 36
2021
Q2 		$22.1M Hold
95,443
– – 0.83% 31
2021
Q1 		$28.7M Hold
95,443
– – 1.08% 25
2020
Q4 		$35.9M Buy
95,443
+23,000
+32% +$8.06M 1.41% 26
2020
Q3 		$22.2M Hold
72,443
– – 1.21% 28
2020
Q2 		$27.2M Sell
72,443
-1,175
-2% -$333K 1.68% 22
2020
Q1 		$16.8M Hold
73,618
– – 1.56% 20
2019
Q4 		$38.9M Hold
73,618
– – 2.95% 11
2019
Q3 		$31.7M Buy
+73,618
New +$47.3M 3.33% 10
2018
Q1 		– Sell
-4,975
Closed -$8.35M – 45
2017
Q4 		$8.35M Sell
4,975
-27,324
-85% -$36.1M 1.01% 26
2017
Q3 		$45.2M Buy
32,299
+2,597
+9% +$3.05M 5.74% 6
2017
Q2 		$33.1M Buy
29,702
+1,439
+5% +$1.19M 5.15% 6
2017
Q1 		$15.3M Hold
28,263
– – 2.61% 13
2016
Q4 		$17.2M Buy
28,263
+4,000
+16% +$2.5M 3.46% 10
2016
Q3 		$17.3M Sell
24,263
-211
-0.9% -$161K 3.27% 11
2016
Q2 		$17.8M Buy
+24,474
New +$16.9M 3.79% 9

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BVF Inc's CBIO Position: Q2 2026 in Review

BVF Inc held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 2,748,763 shares worth $49.5M. The position accounts for 1.27% of the portfolio, ranked #20.

BVF Inc first reported a position in CBIO in Q2 2016 and has held it in 35 quarters since. The position peaked at $50.5M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • BVF Inc held 2,748,763 shares of Crescent Biopharma worth $49.5M as of Q2 2026.
  • BVF Inc left its Crescent Biopharma share count unchanged in Q2 2026.
  • Crescent Biopharma made up 1.27% of BVF Inc's portfolio in Q2 2026, its #20 holding.
  • BVF Inc first reported a position in Crescent Biopharma in Q2 2016 and has held it in 35 quarters since.
  • BVF Inc's Crescent Biopharma position peaked at $50.5M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.